Polynovo Keeps Bull Despite Revenue Miss

Dow Jones
07/27

0122 GMT - PolyNovo keeps its bull at Macquarie despite the wound-treatment specialist missing FY 2026 revenue expectations. The investment bank maintains an outperform rating on the ASX-listed device maker, with analyst Shane Ponraj flagging a stronger-than-anticipated jump in annual cash flow from operations to A$24 million, from A$3 million. With a solid balance sheet and capital-expenditure requirements for PolyNovo's new manufacturing facility largely complete, Ponraj reckons that the company is now well-placed to invest in marketing. He expects ongoing strong order growth. Macquarie cuts its target price 26% to 1.30 Australian dollars. Shares are down 2.3% at A$0.835. (stuart.condie@wsj.com)

 

(END) Dow Jones Newswires

July 26, 2026 21:22 ET (01:22 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10